Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The firm's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The firm's PL9588 is being developed as a topical treatment for glaucoma.